Marshall Wace, LLP Replimune Group, Inc. Transaction History

Marshall Wace, LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$6.87 - $9.31 $551,338 - $747,155	-80,253 Reduced 82.88%	16,581 $135,000
Q4 2023 Feb 14, 2024	SELL	$6.75 - $16.18 $4 Million - $9.59 Million	-592,619 Reduced 85.95%	96,834 $816,000
Q3 2023 Nov 14, 2023	SELL	$15.96 - $22.18 $8.68 Million - $12.1 Million	-543,771 Reduced 44.09%	689,453 $11.8 Million
Q2 2023 Aug 14, 2023	BUY	$15.65 - $24.1 $9.18 Million - $14.1 Million	586,336 Added 90.64%	1,233,224 $28.6 Million
Q1 2023 May 15, 2023	BUY	$17.48 - $29.09 $9.1 Million - $15.1 Million	520,321 Added 411.1%	646,888 $11.4 Million
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $2.16 Million - $3.53 Million	126,567 New	126,567 $3.44 Million
Q2 2022 Aug 15, 2022	SELL	$13.32 - $19.98 $268,304 - $402,457	-20,143 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$15.24 - $29.75 $306,979 - $599,254	20,143 New	20,143 $342,000
Q4 2020 Feb 16, 2021	SELL	$23.5 - $52.65 $500,338 - $1.12 Million	-21,291 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$18.85 - $27.0 $135,814 - $194,535	7,205 Added 51.15%	21,291 $490,000
Q2 2020 Aug 13, 2020	BUY	$9.76 - $25.95 $137,479 - $365,531	14,086 New	14,086 $350,000
Q1 2020 May 15, 2020	SELL	$8.9 - $19.08 $109,567 - $234,893	-12,311 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.61 - $17.21 $142,930 - $211,872	12,311 New	12,311 $177,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $631M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.